King Pharmaceuticals (KG) Misses Q2 EPS by 103c

King Pharmaceuticals (NASDAQ: KG) reported Q2 EPS of ($1.03). Revenue for the quarter came in at $6.7 million.

For earnings history and earnings-related data on King Pharmaceuticals (KG) click here.

You May Also Be Interested In

• Wolfe Research Upgrades Janux Therapeutics (JANX) to Outperform, 'An ARM Out of the Penalty Box'
• JPMorgan Upgrades East Japan Railway Co (9020:JP) to Overweight
• Barclays Upgrades Safestore Holdings Plc. (SAFE:LN) to Overweight